In the German Center for Infection Research (DZIF), scientists from the universities of Tübingen, Münster and Munich join forces and prepare together with the company Hyglos clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: A highly effective protein from bacteria-specific viruses, so-called bacteriophages, shall rapidly kill the bacteria, which frequently occur in the nose. Due to the specific action, the natural microflora is maintained. Such prophylactic treatment of nasal colonization could counteract the spread of especially methicillin-resistant staphylococcus aureus (MRSA) in hospitals and thereby prevent infections in patients.
Every third person, according to expert estimates, carries the bacterium Staphylococcus aureus in their nose - which is not dangerous in the case of healthy individuals, however quickly becomes a problem if the carrier is admitted to a hospital. This since the pathogen can enter for example into wounds in connection with surgery and potentially cause dangerous infections.
In addition there is a large risk of spread of the pathogen as a hospital bug. Especially feared are methicillin-resistant Staphylococcus aureus isolates, abbreviated MRSA, because of their resistance to many of the commonly used antibiotics.
“A rapid detection and effective elimination of MRSA colonization in the nose prior to a hospital stay is a crucial step in combating these hospital germs", so the conviction of Prof. Dr. Karsten Becker at the University Hospital Münster. The bacteria in the nose are increasingly resistant to the currently used antibiotic mupirocin and the duration of the decolonization and follow-up control is around one week. Under such circumstances, no effective MRSA prevention is possible for patients immediately in need of surgery.
Together with the Hyglos GmbH in Bernried and with support from the BMBF, scientists at the University Hospital Münster have developed a specific active substance in recent years and studied its effect: A phage lytic enzyme that is a protein from viruses that infect bacteria, specifically attacks Staphylococcus aureus cells and dissolve them. The protein was synthetically produced and optimized as a "designer protein" with the working name HY-133.
"We do like to describe it as a MRSA-killing protein, even if it sounds somewhat sensational," explains Dr. Wolf-gang Mutter from Hyglos GmbH. In fact, all Staphylococcus aureus cells, whether resistant or not resistant, will be killed by this new active substance within a very short time. And this without the natural microflora in the nose being destroyed nor does resistance develop.
In cooperation with the microbiologist Prof. Dr. Andreas Peschel, who coordinates the DZIF research on "Healthcare-associated and antibiotic-resistant infections", the active substance will now be prepared for clinical testing. More than 1.5 million euros will be provided for HY-133 development within the DZIF:
The substance will first be manufactured under GMP guidelines (manufac-turing practice according to pharmaceutical standards) and subsequently be test-ed for preclinical toxicology. The pharmacist Prof. Dr. Gerhard Winter at the LMU Munich will develop a stable formulation, so that the substance may be conven-iently and safely administered as a gel or in any other form to the patient.
The project will be conducted in view of subsequent clinical trials, in which the rapid decolonization of Staphylococcus aureus strains will be studied in the nasal flora of volunteers. "In addition to new antibiotics and vaccines we urgently need specific agents for decolonization of problematic germs. The HY-133 protein is a highly innovative active substance for this purpose, which could lead to many simi-lar development programs", Prof. Dr. Andreas Peschel adds.
That the fight against resistant hospital germs is taken very seriously at the political level, is reflected in the coming week: At the G7 summit in Elmau the topic antibi-otic resistance is on the agenda.
In case you need any pictures, please contact:
Prof. Dr. Andreas Peschel
University of Tübingen
DZIF-Coordinator „Healthcare-associated and antibiotic-resistant infections“
T +49 7071-29-81515
Prof. Dr. Karsten Becker
University Hospital Münster
T +49(0) 251-83-55375
Prof. Dr. Gerhard Winter
Ludwig Maximilian University of Munich
T +49(0) 89-2180-77022
Dr. Wolfgang Mutter
Hyglos GmbH, Bernried am Starnberger See
Ms. Karola Neubert and Ms. Janna Schmidt
At the German Center for Infection Research (DZIF) nationwide around 300 scien-tists from 32 institutions jointly develop new approaches for prevention, diagnosis and treatment of infectious diseases. One of the focal points is the research on hospital germs and antibiotic-resistant bacteria. The DZIF is funded by the BMBF. More information on www.dzif.de
University of Tübingen – Infectious Diseases and Microbiology form a major focus of research at the University of Tübingen, especially in the Interfaculty Institute for Microbiology and Infection Medicine (IMIT). The study of staphylococci, bacte-ria that often develop resistance to antibiotics and cause infections in the hospital, is a particular focus of the IMIT researchers. www.uni-tuebingen.de
University Hospital Münster (UKM) represents cutting-edge medicine in the German hospital landscape as well as research at the highest international level. Important research priorities of the UKM Institute of Medical Microbiology are staphylococci - pathogens and infections - as well as diagnostics, typing, character-ization and susceptibility testing of microorganisms. www.klinikum.uni-muenster.de
Ludwig Maximilian University of Munich (LMU), Department of Pharmacy - The development of stable formulations for protein drugs and the administration of new biotech drugs in sustained release forms or their local application are key research areas in Pharmaceutical Technology at the LMU. Only with appropriate forms of preparation it will be possible in the end, to successfully apply sensitive substances such as the new phage lytic enzyme. www.uni-muenchen.de
Hyglos GmbH is a biotechnology company based in the Biotechnology Center Bernried south of Munich. With its proprietary technology the Hyglos scientists develop highly specific bacteriophage-based agents for the detection and elimina-tion of harmful bacteria and bacterial toxins. Hyglos is an IAFP Innovation awardee for such technological advances. www.hyglos.com
Karola Neubert | idw - Informationsdienst Wissenschaft
Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München
Second cause of hidden hearing loss identified
20.02.2017 | Michigan Medicine - University of Michigan
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
22.02.2017 | Power and Electrical Engineering
22.02.2017 | Life Sciences
22.02.2017 | Innovative Products